Fatal relapse of disseminated strongyloidiasis in an HIV-positive patient, despite ivermectin treatment.
There are no established guidelines for the treatment of disseminated strongyloidiasis in immunosuppressed patients, and many different treatment regimens have been used. Here, the case of a 48-year-old, HIV-positive, Congolese man, who was hospitalized for disseminated tuberculosis but developed life-threatening disseminated strongyloidiasis, is described. This patient died, with relapsing disseminated strongyloidiasis, 3 months after being treated with ivermectin. The reasons for this poor outcome and the various treatment options for strongyloidiasis in HIV-infected patients are discussed.
Mattioni
S
S
Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, 47-83 Boulevard de l'Hôpital, F-75013 Paris, France.
Valin
N
N
Cracco
C
C
Thellier
M
M
Danis
M
M
Caumes
E
E
D000818:Animals; D000969:Antinematodal Agents / Q000627:therapeutic use*; D017809:Fatal Outcome; D006679:HIV Seropositivity; D006801:Humans; D016867:Immunocompromised Host; D007559:Ivermectin / Q000627:therapeutic use*; D008174:Lung Diseases, Parasitic / Q000188:drug therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D017171:Strongyloides stercoralis; D013322:Strongyloidiasis / Q000188:drug therapy* / Q000821:virology; D014376:Tuberculosis / Q000469:parasitology / Q000821:virology
D000969:Antinematodal Agents; D007559:Ivermectin